Suppr超能文献

降压药类型引起的升压反应。

Pressor responses to antihypertensive drug types.

机构信息

Department of Epidemiology, Albert Einstein College of Medicine, Bronx, New York, USA.

出版信息

Am J Hypertens. 2010 Sep;23(9):1031-7. doi: 10.1038/ajh.2010.114. Epub 2010 Aug 19.

Abstract

BACKGROUND

Pressor responses to antihypertensive drugs are not addressed in treatment guidelines although they have been described in various clinical situations. We now report the incidence of pressor responses to initiation of monotherapy using four antihypertensive drug types, and the influence of plasma renin activity (PRA) status, among participants in a worksite-based antihypertensive treatment program.

METHODS

Systolic blood pressure (SBP) response was evaluated among 945 participants with no prior treatment who were given either a diuretic or calcium-channel blocker (natriuretic antivolume V drugs, n = 537) or a beta-blocker or angiotensin-converting enzyme (ACE) inhibitor (antirenin R drugs n = 408). PRA was categorized by low, middle, and high tertiles (L, M, and H). SBP rise > or =10 mm Hg was considered pressor.

RESULTS

More pressor responses occurred with R than V drugs (11% vs. 5%, P = 0.001). L, M, and H renin tertiles had similar frequencies with V drugs (6, 4, and 6%), but low and middle tertiles given R had greater pressor frequencies (17% P = 0.003 vs. V and 10% P = 0.02 vs. V). Treatment SBP > or =160 mm Hg occurred more frequently with R than V drugs (19% vs. 13%; P = 0.007); moreover, in the lowest renin tertile 35% R vs. 13% V (P = 0.001) had SBP > or =160 mm Hg. Treatment SBP <130 mm Hg was more frequent in V patients in the lowest tertile (18% vs. 5%; P = 0.003), and in R patients in the highest tertile (26% vs. 12%, P = 0.002).

CONCLUSIONS

Pressor responses to antihypertensive monotherapy occur sufficiently frequently to be of concern, especially in lower renin patients given a beta-blocker or ACE inhibitor (ACEI).

摘要

背景

尽管在各种临床情况下都描述了降压药物的升压反应,但治疗指南并未对此进行阐述。我们现在报告在一项基于工作场所的降压治疗计划中,使用四种降压药物类型开始单药治疗时升压反应的发生率,以及血浆肾素活性 (PRA) 状态的影响。

方法

评估了 945 名无既往治疗的参与者的收缩压 (SBP) 反应,这些参与者分别接受利尿剂或钙通道阻滞剂(利钠抗容积 V 药物,n = 537)或β-受体阻滞剂或血管紧张素转换酶 (ACE) 抑制剂(肾素 R 药物,n = 408)。PRA 按低、中、高三分位数 (L、M 和 H) 进行分类。SBP 升高 >或=10mmHg 被认为是升压。

结果

R 药物比 V 药物更易发生升压反应(11%比 5%,P=0.001)。L、M 和 H 肾素三分位在 V 药物中具有相似的频率(6%、4%和 6%),但给予 R 的低和中三分位有更高的升压频率(17% P=0.003 比 V 和 10% P=0.02 比 V)。R 药物的治疗 SBP >或=160mmHg 比 V 药物更常见(19%比 13%;P=0.007);此外,在最低肾素三分位中,35%的 R 比 13%的 V(P=0.001)的 SBP >或=160mmHg。在最低三分位的 V 患者中,SBP <130mmHg 的治疗更为频繁(18%比 5%;P=0.003),而在最高三分位的 R 患者中更为频繁(26%比 12%;P=0.002)。

结论

降压药物单药治疗时的升压反应发生频率足够高,值得关注,尤其是在给予β受体阻滞剂或 ACEI 的低肾素患者中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验